Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTIMIDIS - Cefazolin mediastinal distribution using microdialysis
2025-521988-13-00Phase 4Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2026
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cefazolin in Infection and bacterial disease, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Population pharmacokinetic parameters and inter-individual variability. Planned start Jun 2026; status: authorised.
02
Drugs
cefazolin
03
Conditions
Infectionbacterial disease
Beyond the preview
Go deeper on 2025-521988-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521988-13-00.